How should menopause-related SUI be optimally managed?

• A. Systemic therapy is preferred for tissue quality.
• B. Local vaginal estrogen for tissue quality, combined with PFMT and other modalities; avoid systemic therapy if not indicated.
• C. Surgery should be first-line.
• D. No treatment is recommended.

Answer: (B)

In menopause-related SUI, the foundational issue is thinning and fragility of the vaginal and urethral tissues from estrogen deficiency. Restoring tissue quality is a key first step. Local vaginal estrogen directly acts on the genital tissues, increasing epithelial thickness, moisture, and blood flow, and helping to rebuild supportive connective tissue around the urethra. This improved tissue quality enhances the urethral closure mechanism and the support the pelvic floor provides.

Pairing this with pelvic floor muscle training strengthens the muscles that support the bladder and urethra, reducing leakage during activities that raise pressure in the abdomen. In addition, other noninvasive strategies—such as bladder training, lifestyle modifications, and, if needed, a pessary for mechanical support—complement the approach and address different contributing factors.

Systemic estrogen is avoided when not clearly indicated for other reasons because it carries broader risks and isn’t necessary for improving tissue quality in this context; local estrogen provides the targeted benefit with fewer systemic effects. Surgery is not a first-line option for menopause-related SUI, and withholding treatment isn’t appropriate when symptoms can be effectively managed with conservative measures.

So, combining local vaginal estrogen to improve tissue quality with pelvic floor training (and other conservative modalities) offers the best, least risky approach.